Overview of expression of hepatitis B surface antigen in transgenic plants.
Hepatitis B virus (HBV), a pathogen for chronic liver infection, afflicts more than 350 million people world-wide. The effective way to control the virus is to take HBV vaccine. Hepatitis B surface antigen (HBsAg) is an effective protective antigen suitable for vaccine development. At present, "edible" vaccine based on transgenic plants is one of the most promising directions in novel types of vaccines. HBsAg production from transgenic plants has been carried out, and the transgenic plant expression systems have developed from model plants (such as tobacco, potato and tomato) to other various plant platforms. Crude or purified extracts of transformed plants have been found to conduct immunological responses and clinical trials for hepatitis B, which gave the researches of plant-based HBsAg production a big boost. The aim of this review was to summarize the recent data about plant-based HBsAg development including molecular biology of HBsAg gene, selection of expression vector, the expression of HBsAg gene in plants, as well as corresponding immunological responses in animal models or human.
Guan
Zheng-jun
ZJ
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education Northwest University, Xi'an 710069, China. zhengjunguan@126.com
Guo
Bin
B
Huo
Yan-lin
YL
Guan
Zheng-ping
ZP
Wei
Ya-hui
YH
D000818:Animals; D005822:Genetic Vectors; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D030821:Plants, Genetically Modified / Q000276:immunology* / Q000378:metabolism
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines